Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;35(1):e15185.
doi: 10.1111/dth.15185. Epub 2021 Nov 30.

Treating pediatric cutaneous Leishmania tropica with systemic liposomal amphotericin B: A retrospective, single-center study

Yehonatan Noyman  1   2 , Assi Levi  1   2 , Dan Ben Amitai  2   3 , Shiran Reiss-Huss  2   3 , Fareed Sabbah  2   3 , Emmilia Hodak  1   2 , Tomer Mimouni  2 , Rivka Friedland  2   3
Affiliations

Treating pediatric cutaneous Leishmania tropica with systemic liposomal amphotericin B: A retrospective, single-center study

Yehonatan Noyman et al. Dermatol Ther. 2022 Jan.

Abstract

Leishmania tropica (L. tropica) cutaneous leishmaniasis (CL) is associated with high morbidity and low response rate to therapy, especially in pediatric patients. Intravenous (IV) liposomal amphotericin B (LAmB) has been used off-label as a treatment for L. tropica CL for many years. However, data regarding its efficacy and safety in children is lacking. In order to evaluate the efficacy and safety of IV LAmB for treating pediatric patients with L. tropica, we retrospectively reviewed electronic medical records of 24 children who were diagnosed with L. tropica CL and treated with IV LAmB during 2014-2020, at a tertiary medical center in Israel. Fourteen (58%) completed the treatment protocol and 10 (42%) experienced an infusion-related adverse event (IRAE) leading to treatment termination. Complete response was noted in 6/14 (43%) patients, while 8/14 (57%) failed to respond. Lower response rate was noted in lesions involving the mid-facial area. The relatively low response rate is speculated to result from a low dose of LAmB, short follow-up period, and difficult to treat anatomic locations. The observation of a lower response rate for mid-facial lesions should be validated in larger cohorts. The highrisk of IRAE should be considered in physician decisions regarding this treatment.

Keywords: AmBisome; cutaneous Leishmania tropica; liposomal amphotericin B.

PubMed Disclaimer

References

REFERENCES

    1. Jaffe CL, Baneth G, Abdeen ZA, Schlein Y, Warburg A. Leishmaniasis in Israel and The Palestinian Authority. Trends Parasitol. 2004;20(7):328-332. doi:10.1016/j.pt.2004.05.001
    1. Solomon M, Schwartz E. Cutaneous Leishmaniasis in Israel 2016 - an update. Harefuah. 2016;155(10):626-631. http://www.ncbi.nlm.nih.gov/pubmed/28530056
    1. Shani-Adir A, Kamil S, Rozenman D, et al. Leishmania tropica in northern Israel: a clinical overview of an emerging focus. J Am Acad Dermatol. 2005;53(5):810-815. doi:10.1016/j.jaad.2005.07.026
    1. Hepburn NC. Cutaneous leishmaniasis. Clin Exp Dermatol. 2000;25(5):363-370. doi:10.1046/j.1365-2230.2000.00664.x
    1. Klaus S, Axelrod O, Jonas F, Frankenburg S. Changing patterns of cutaneous leishmaniasis in Israel and neighbouring territories. Trans R Soc Trop Med Hyg. 1994;88(6):649-650. doi:10.1016/0035-9203(94)90209-7

LinkOut - more resources